Opinion

Video

Common Adverse Reactions to EGFR Therapy

Alan Chin, PharmD, BCOP, presents an overview of the most prevalent and common adverse reactions associated with EGFR-targeted therapies in metastatic NSCLC and shares strategies to mitigate toxicities, with a focus on managing dermatologic events such as rash and itching.

  1. Provide a broad overview of common adverse effects associated with EGFR-targeted therapies in metastatic NSCLC.
  2. What proactive strategies do you recommend for preventing dermatologic toxicities, such as rash and acneiform eruptions, in patients receiving EGFR-targeted therapies?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
3 experts are featured in this series.
Related Content
Non–small cell lung cancer (NSCLC) -- Image credit: Crystal light | stock.adobe.com
September 3rd 2025

Iza-Bren Receives FDA Breakthrough Therapy Designation for EGFR-Mutated NSCLC

Gillian McGovern, Associate Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
September 3rd 2025

Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC

Alexandra Gerlach, Associate Editor Kevin Chen, PharmD Amanda Cass, PharmD, BCPS, BCOP
Small cell lung cancer (SCLC) -- Image credit: Arif Biswas | stock.adobe.com
September 3rd 2025

MET Inhibitor With Chemoimmunotherapy Overcomes Treatment Resistance in Some Patients With SCLC

Gillian McGovern, Associate Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
September 3rd 2025

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Sunvozertinib Brings Changes in Non-Small Cell Lung Cancer Treatment
September 3rd 2025

Sunvozertinib Brings Changes in Non-Small Cell Lung Cancer Treatment

Amy C. Nieto, BS, PharmD Candidate
X-ray 3D visualization of lungs with tumors | Image Credit: © Moon Story - stock.adobe.com
September 3rd 2025

Zongertinib Approved by FDA for Patients With Nonsquamous NSCLC With HER2 TKD Mutations

Alexandra Gerlach, Associate Editor
© 2025 MJH Life Sciences

All rights reserved.